# Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

> **NCT02356458** · PHASE1,PHASE2 · TERMINATED · sponsor: **Swiss Cancer Institute** · enrollment: 58 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT02356458
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08-31
- **Primary completion:** 2021-03-30
- **Final completion:** 2021-03-30
- **Target enrollment:** 58 (ACTUAL)
- **Why stopped:** SAKK Board decision of 14th November 2020 due to financial reasons.
- **Last updated:** 2022-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02356458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02356458, "Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02356458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*